Company intelligence / Profile preview

Neurive

Gimhae-si, Gyeongsangnam-do, South Korealinkedin.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Neurive has developed a non-invasive vagus nerve stimulation device ("Soricle") for the treatment of tinnitus and potentially other degenerative brain diseases. A clinical trial validating the brain mechanism by this approach has been completed, and published literature supports its efficacy in modulating neural activity during cognitive tasks[1][4].

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy (non-invasive vagus nerve stimulation)Digital therapeuticsElectroceutical therapy
Industry: Therapeutic Medical Devices

Partnerships

Not specified in available sources[1][5]

Beyond the preview

Go deeper on Neurive.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurive.

Explore the full profile